Edgar Hernández-Zamora, María de la Luz Arenas-Sordo, Rosa Elena Escobar-Cedillo, Norma Celia González-Huerta, Norberto Leyva-García, Rogelio Maldonado-Rodríguez

Idioma: Español
Referencias bibliográficas: 55
Paginas: 383-389
Archivo PDF: 156.43 Kb.

RESUMEN

Antecedentes: La neuropatía periférica de Charcot-Marie-Tooth (CMT) es la enfermedad hereditaria más común del sistema nervioso periférico humano. El subtipo más frecuente, CMT1A, es asociado a una duplicación de un fragmento de ~1.5 Mb en 17p11.2-p12, que incluye al gen PMP22.
Objetivo: Describir diferentes estrategias para el diagnóstico clínico y molecular de CMT1A en pacientes del Instituto Nacional de Rehabilitación.
Material y métodos: A 17 pacientes estudiados clínica y electrofisiológicamente que reunieron los criterios para CMT1, se les realizó el estudio molecular mediante electroforesis capilar para detectar la duplicación del gen PMP22.
Resultados: Los estudios clínico, bioquímico y electrofisiológico ofrecieron los criterios para establecer el diagnóstico de CMT1. Con la electroforesis capilar se detectó la duplicación del gen PMP22 en siete pacientes que fueron diagnosticados clínica y electrofisiológicamente como CMT1, pudiendo llegar al diagnóstico de CMT1A. Todas las duplicaciones identificadas fueron corroboradas mediante hibridación in situ fluorescente.
Conclusión: Los resultados nos permiten asegurar que la electroforesis capilar es un método fácil y confiable para detectar la duplicación del gen PMP22. Además, el aplicar diferentes estrategias tanto clínicas, electrofisiológicas y moleculares en este tipo de pacientes, nos permitieron establecer el diagnóstico correcto y ofrecer asesoramiento genético adecuado.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Salamanca-Gómez F. Avances en el estudio de las enfermedades neurodegenerativas. Gac Med Mex 2001;137:487-488.

2. Benstead TJ, Grant IA. Progress in clinical neurosciences: Charcot-Marie-Tooth disease and related inherited peripheral neuropathies. Can J Neurol Sci 2001;28:199-214.

3. Sevilla T. Genética de la enfermedad de Charcot-Marie-Tooth tipo 1, de las neuropatías focales hereditarias y de las neuropatías hereditarias motoras distales. Rev Neurol 2000;30:71-79.

4. Nodera H, Bostock H, Kuwabara S, Sakamoto T, Asanuma K, Jia-Ying S, et al. Nerve excitability properties in Charcot-Marie-Tooth disease type 1A. Brain 2004;127:203-211.

5. Rodríguez-García PL, Rodríguez-Pupo L, Rodríguez-García D. Técnicas clínicas para el examen físico neurológico. I. Organización general, nervios craneales y nervios raquídeos periféricos. Rev Neurol 2004;39:757-766.

6. Rodríguez-García PL, Rodríguez-Pupo L, Rodríguez-García D. Técnicas clínicas para el examen físico neurológico. II. Funciones motora y refleja. Rev Neurol 2004;39:848-859.

7. Rodríguez-García PL, Rodríguez-Pupo L, Rodríguez-García D. Técnicas clínicas para el examen físico neurológico. III. Funciones sensoriales. Rev Neurol 2004;39:966-971.

8. Amo-Usanos C, Martín-Jiménez S, Basurte-Villamor P, Puente-Muñoz AI, Amo-Merino P, Amo-Usanos I, et al. Sobre el diagnóstico de las neuropatías periféricas: estudio clínico y neurofisiológico. Rev Neurol 2001;32:123-126.

9. Berghoff C, Berghoff M, Leal A, Morera B, Barrantes R, Reis A, et al. Clinical and electrophysiological characteristics of autosomal recessive axonal Charcot- Marie-Tooth disease (ARCMT2B) that maps to chromosome 19q13.3. Neuromuscul Disord 2004;14:301-306.

10. Lupski JR, de Oca-Luna RM, Slaugenhaupt S, Pentao L, Guzzetta V, Trask BJ, et al. DNA duplication associated with Charcot-Marie-Tooth disease type 1A. Cell 1991;66:219-232.

11. Hanemann CO, Stoll G, D’Urso D, Fricke W, Martin JJ, Van Broeckhoven C, et al. Peripheral myelin protein-22 expression in Charcot-Marie Tooth disease type 1a sural nerve biopsies. J Neurosci Res 1994;37:654-659.

12. Marques WJ, Sweeney MG, Wood NW. Thr(118)Met amino acid substitution in the peripheral myelin protein 22 does not influence the clinical phenotype of Charcot-Marie-Tooth disease type 1A due to the 17p11.2- p12 duplication. Braz J Med Biol Res 2003;36:1403-1407.

13. Suter U, Moskow JJ, Welcher AA, Snipes GJ, Kosaras B, Sidman RL, et al. A leucine-to-proline mutation in the putative first transmembrane domain of the 22-kDa peripheral myelin protein in the trembler-J mouse. Proc Natl Acad Sci 1992;89:4382-4386.

14. Suter U, Snipes GJ, Schoener-Scott R, Welcher AA, Pareek S, Lupski JR, et al. Regulation of tissue-specific expression of alternative peripheral myelin protein-22 (PMP22) gene transcripts by two promoters. J Biol Chem 1994;269:25795-25808.

15. Suter U, Welcher AA, Ozcelik T, Snipes GJ, Kosaras B, Francke U, et al. Trembler mouse carries a point mutation in a myelin gene. Nature 1992;356:241-244.

16. Niemann S, Sereda MW, Suter U, Griffiths IR, Nave KA. Uncoupling of myelin assembly and schwann cell differentiation by transgenic overexpression of peripheral myelin protein 22. J Neurosci 2000;20:4120-4128.

17. Chies R, Nobbio L, Edomi P, Schenone A, Schneider C, Brancolini C. Alterations in the Arf6-regulated plasma membrane endosomal recycling pathway in cells overexpressing the tetraspan protein Gas3/PMP22. J Cell Sci 2003;116:987-999.

18. Sancho S, Young P, Suter U. Regulation of Schwann cell proliferation and apoptosis in PMP22-deficient mice and mouse models of Charcot-Marie-Tooth disease type 1A. Brain 2001;124:2177-2187.

19. Robertson AM, Perea J, McGuigan A, King RH, Muddle JR, Gabreels- Festen AA, et al. Comparison of a new pmp22 transgenic mouse line with other mouse models and human patients with CMT1A. J Anat 2002;200:377-390.

20. Reiter LT, Murakami T, Koeuth T, Gibbs RA, Lupski JR. The human COX10 gene is disrupted during homologous recombination between the 24 kb proximal and distal CMT1A-REPs. Hum Mol Genet 1997;6:1595-1603.

21. Cruz-Medina E, Soria-Batida MA. Resúmenes de los trabajos de investigación presentados en la XVI Jornadas Nacionales de Médicos Residentes en Medicina de Rehabilitación: Número de casos nuevos de enfermedades neuromusculares atendidos en el Centro Nacional de Rehabilitación y Ortopedia, Instituto Nacional de Neurología y Hospital Infantil de México. Rev Mex Med Fis Rehab 2000;12:6-9.

22. Papazian O. Alfonso I, García F. Evaluación neurofisiológica de los niños con neuropatías periférica. Rev Neurol 2002;35:254-268.

23. Dumitru D. Electrodiagnostic medicine. Philadelphia:Hanlel & Belfus, Inc.; 2001.

24. DeLisa JA, Lee HJ, Baran EM, Lai KS, Spielholz. Manual of nerve conduction velocity and clinical neurophysiology. 3a. ed. New York: Raven Press; 1994.

25. Szasz G, Gerhardt W, Gruber W. Creatine kinase in serum: 3. Further study of adenylate kinase inhibitors. Clin Chem 1977;23:1888-1892.

26. Kasamatsu T. Studies on the serum aldolase activity in workers with muscle disorders caused by vibration work. Sangyo Igaku 1983;25:493-502.

27. Amador E, Dorfman LE, Wacker WE. Serum lactic dehydrogenase activity: an analytical assessment of current assays. Clin Chem 1963;12:391-399.

28. Wroblewski F, LaDue JS. Serum glutamic pyruvic transaminase in cardiac with hepatic disease. Proc Soc Exp Biol Med 1956;91:569-571.

29. Saris NE. International Federation of Clinical Chemistry (IFCC). The role of the IFCC-section in Clinica Chimica Acta. Clin Chim Acta 1975;61:F1.

30. Bowers GN J, McComb RB. Measurement of total alkaline phosphatase activity in human serum. Clin Chem 1975;21:1988-1995.

31. Shaffer LG, Kennedy GM, Spikes AS, Lupski JR. Diagnosis of CMT1A duplications and HNPP deletions by interphase FISH: implications for testing in the cytogenetics laboratory. Am J Med Genet 1997;69:325-331.

32. Verma RS, Babú A. Human chromosomes: Manual of basic techniques. New York: Pergamon Press; 1989. pp. 5-9.

33. Buffone GJ, Darlington GJ. Isolation of DNA from biological specimens without extraction with phenol. Clin Chem 1985;31:164-165.

34. Chamberlain JS, Gibbs RA, Ranier JE, Nguyen PN, Caskey CT. Deletion screening of the Duchenne muscular dystrophy locus via multiplex DNA amplification. Nucleic Acids Res 1988;16:11141-11156.

35. Chamberlain JS, Gibbs RA, Ranier JE, Caskey CT. Multiplex PCR for the diagnosis of Duchenne muscular dystrophy. EUA: Academic Press; 1990.

36. Roa BB, García CA, Pentao L, Killian JM, Trask BJ, Suter U, et al. Evidence for a recessive PMP22 point mutation in Charcot-Marie-Tooth disease type 1A. Nat Genet 1993;5:189-194.

37. Roa BB, García CA, Suter U, Kulpa DA, Wise CA, Mueller J, et al. Charcot-Marie-Tooth disease type 1A. Association with a spontaneous point mutation in the PMP22 gene. N Engl J Med 1993;329(2):96-101.

38. Castagnino JM. Electroforesis capilar. Bioquimia 2000;25:13-32.

39. Yau SC, Bobrow M, Mathew CG, Abbs SJ. Accurate diagnosis of carriers of deletions and duplications in Duchenne/Becker muscular dystrophy by fluorescent dosage analysis. J Med Genet 1996;33:550-558.

40. Lynn AM, Jain CK, Kosalai K, Barman P, Thakur N, Batra H, et al. An automated annotation tool for genomic DNA sequences using GeneScan and BLAST. J Genet 2001;80:9-16.

41. Pereira-Vianello BR, Grattapaglia D. Cost-effective method to synthesize a fluorescent internal DNA standard for automated fragment sizing. Biotechniques 2001;31:793-800.

42. Bhattacharya A, Bhattacharya S, Joshi A, Ramachandran S, Ramaswamy R. Identification of parasitic genes by computational methods. Parasitol Today 2000;16:127-131.

43. Mansfield ES, Blasband A, Kronick MN, Wrabetz L, Kaplan P, Rappaport E, et al. Fluorescent approaches to diagnosis of Lesch-Nyhan syndrome and quantitative analysis of carrier status. Mol Cell Probes 1993;7:311-324.

44. Mansfield ES, Robertson JM, Lebo RV, Lucero MY, Mayrand PE, Rappaport E, et al. Duchenne/Becker muscular dystrophy carrier detection using quantitative PCR and fluorescence-based strategies. Am J Med Genet 1993;48:200-208.

45. Mansfield ES, Vainer M, Harris DW, Gasparini P, Estivill X, Surrey S, et al.Rapid sizing of polymorphic microsatellite markers by capillary array electrophoresis. J Chromatogr A 1997;781:295-305.

46. Sevilla T, Vilchez JJ. Different phenotypes of Charcot-Marie-Tooth disease caused by mutations in the same gene. Are classical criteria for classification still valid? Neurologia 2004;19:264-271.

47. Palau F, Cuesta A, Pedrola L. Avances en la genética molecular de las neuropatías hereditarias. Rev Neurol 2002;35:246-253.

48. López-Pison J, Rebage V, Baldellou-Vázquez A, Capablo-Liesa JL, Colomer J, Calvo MT, et al. Hereditary neuromuscular diseases in paediatrics. Our experience over the last 14 years. Rev Neurol 2005;41:145-150.

49. Salinero-Paniagua E, Esteban-García A, Traba A, Palencia-Herrejón E, Garzo-Fernández C, Prieto-Montalvo J. Modified aspiration needle muscular biopsy in neuromuscular diseases. Use and advantages over open surgical biopsy. Rev Neurol 2004;39:821-825.

50. Blair IP, Nash J, Gordon MJ, Nicholson GA. Prevalence and origin of the novo duplications in Charcot-Marie-Tooth disease type 1 A : First report of a de novo duplication with a maternal origin. Am J Hum Genet 1996;58:472-476.

51. Xiao J, Tang B, Xia J. PCR in the gene diagnosis of Charcot-Marie-Tooth disease. Zhonghua Yi Xue Za Zhi 2001;81:138-141.

52. Potocki L, Chen KS, Park SS, Osterholm DE, Withers MA, Kimonis V, et al. Molecular mechanism for duplication 17p11.2- the homologous recombination reciprocal of the Smith-Magenis microdeletion. Nat Genet 2000;24:84-87.

53. Choi JR, Lee WH, Sunwoo IN, Lee EK, Lee CH, Lim JB. Effectiveness of realtime quantitative PCR compare to repeat PCR for the diagnosis of Charcot- Marie-Tooth Type 1A and hereditary neuropathy with liability to pressure palsies. Yonsei Med J 2005;46:347-352.

54. Lin CY, Su YN, Lee CN, Hung CC, Cheng WF, Lin WL, et al. A rapid and reliable detection system for the analysis of PMP22 gene dosage by MP/ DHPLC assay. J Hum Genet 2006;51:227-235.

55. Grandis M, Shy ME. Current Therapy for Charcot-Marie-Tooth Disease. Curr Treat Options Neurol 2005;7:23-31.